Literature DB >> 19447129

Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians.

Scott M Rawls1, Timmy Thomas, Mobilaji Adeola, Tanvi Patil, Natalie Raymondi, Asha Poles, Michael Loo, Robert B Raffa.   

Abstract

The mechanism of anticonvulsant action of topiramate includes inhibition of glutamate-activated ion channels. The evidence is most convincing for direct inhibitory action at the ionotropic AMPA (alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid) and kainate ((2S,3S,4S)-3-(Carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylic acid) glutamate receptor subtypes. Less direct connection has been made to the NMDA (N-Methyl-d-aspartate) subtype. In the present study, we demonstrate that NMDA and AMPA produce concentration-dependent seizure-like activity in planarians, a type of flatworm which possesses mammalian-like neurotransmitters. In contrast, planarians exposed to the inhibitory amino acid, glycine, did not display pSLA. For combination experiments, topiramate significantly reduced planarian seizure-like activity (pSLA) produced by NMDA or AMPA. Additionally, NMDA-induced pSLA was antagonized by either an NMDA receptor antagonist (MK-801) or AMPA receptor antagonist (DNQX), thus suggesting that NMDA-induced pSLA was mediated by NMDA and non-NMDA receptors. The present results provide pharmacologic evidence of a functional inhibitory action of topiramate on glutamate receptor activity in invertebrates and provide a sensitive, quantifiable end-point for studying anti-seizure pharmacology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447129     DOI: 10.1016/j.pbb.2009.05.005

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  17 in total

1.  Mephedrone ("bath salt") pharmacology: insights from invertebrates.

Authors:  L Ramoz; S Lodi; P Bhatt; A B Reitz; C Tallarida; R J Tallarida; R B Raffa; S M Rawls
Journal:  Neuroscience       Date:  2012-01-20       Impact factor: 3.590

2.  Treatment of bipolar disorder with comorbid migraine.

Authors:  Abigail Ortiz; Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2010-01       Impact factor: 6.186

3.  Behavioral effects of Splenda, Equal and sucrose: Clues from planarians on sweeteners.

Authors:  Kevin Ouyang; Sunil Nayak; Young Lee; Erin Kim; Michael Wu; Christopher S Tallarida; Scott M Rawls
Journal:  Neurosci Lett       Date:  2016-11-11       Impact factor: 3.046

4.  Topiramate-antagonism of L-glutamate-induced paroxysms in planarians.

Authors:  Robert B Raffa; Kristin E Finno; Christopher S Tallarida; Scott M Rawls
Journal:  Eur J Pharmacol       Date:  2010-09-19       Impact factor: 4.432

5.  Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay.

Authors:  Chris Tallarida; Kevin Song; Robert B Raffa; Scott M Rawls
Journal:  Amino Acids       Date:  2011-08-18       Impact factor: 3.520

6.  Nicotine behavioral pharmacology: clues from planarians.

Authors:  Scott M Rawls; Tanvi Patil; Christopher S Tallarida; Steven Baron; Myongji Kim; Kevin Song; Sara Ward; Robert B Raffa
Journal:  Drug Alcohol Depend       Date:  2011-05-06       Impact factor: 4.492

7.  Glutamate signaling through the kainate receptor enhances human immunoglobulin production.

Authors:  Jamie L Sturgill; Joel Mathews; Peggy Scherle; Daniel H Conrad
Journal:  J Neuroimmunol       Date:  2011-01-06       Impact factor: 3.478

8.  β-lactamase inhibitors display anti-seizure properties in an invertebrate assay.

Authors:  S M Rawls; F Karaca; I Madhani; V Bhojani; R L Martinez; M Abou-Gharbia; R B Raffa
Journal:  Neuroscience       Date:  2010-06-23       Impact factor: 3.590

Review 9.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

10.  Planarians require an intact brain to behaviorally react to cocaine, but not to react to nicotine.

Authors:  O R Pagán; S Deats; D Baker; E Montgomery; G Wilk; M Tenaglia; J Semon
Journal:  Neuroscience       Date:  2013-05-14       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.